特布他林联合布地奈德治疗新生儿肺炎的效果

Effects of Terbutaline combined with Budesonide in treatment of neonatal pneumonia

目的:观察特布他林联合布地奈德治疗新生儿肺炎患儿的效果。方法:选取2019年12月至2022年12月该院收治的60例新生儿肺炎患儿进行前瞻性研究,按随机数字表法将其分为对照组和研究组各30例。对照组给予布地奈德治疗,研究组在对照组基础上联合特布他林治疗,比较两组临床疗效、临床症状缓解时间、住院时间,治疗前后炎性因子[C反应蛋白(CRP)、白细胞介素-6(IL-6)]水平、血气分析指标[动脉血二氧化碳分压(PaCO_(2))、动脉血氧分压(PaO_(2))]水平、肺功能指标[潮气量(VT)、呼吸频率(RR)、呼吸峰流速(PEF)、达峰时间比(TPTEF/TE)、达峰容积比(VPEF/VE)]水平,以及不良反应发生率。结果:研究组治疗总有效率为96.67%(29/30),高于对照组的73.33%(22/30),差异有统计学意义(P<0.05);研究组气促、鼻阻、咳嗽、肺部啰音等临床症状缓解时间以及住院时间均短于对照组,差异有统计学意义(P<0.05);治疗后,两组CRP、IL-6水平均低于治疗前,且研究组低于对照组,差异有统计学意义(P<0.05);治疗后,两组PaCO_(2)水平均低于治疗前,且研究组低于对照组,两组PaO_(2)水平均高于治疗前,且研究组高于对照组,差异有统计学意义(P<0.05);治疗后,两组VT、TPTEF/TE、VPEF/VE水平均高于治疗前,且研究组高于对照组,两组RR、PEF水平均低于治疗前,且研究组低于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:特布他林联合布地奈德治疗新生儿肺炎患儿可提高治疗总有效率,缩短临床症状缓解时间和住院时间,降低炎性因子水平,改善血气分析指标和肺功能指标水平,其效果优于单纯布地奈德治疗。

Objective:To observe effects of Terbutaline combined with Budesonide in treatment of neonatal pneumonia.Methods:A prospective study was conducted on 60 children with neonatal pneumonia admitted to the hospital from December 2019 to December 2022.They were divided into control group and study group according to the random number table method,30 cases in each.The control group was treated with Budesonide,while the study group was treated with Terbutaline on the basis of that of the control group.The clinical efficacy,the remission time of clinical symptoms,the hospitalization time,the levels of inflammatory factors[C-reactive protein(CRP),interleukin-6(IL-6)],arterial blood gas analysis indexes[arterial partial pressure of carbon dioxide(PaCO_(2)),arterial partial pressure of oxygen(PaO_(2))]and lung function indexes[tidal volume(VT),respiratory rate(RR),peak expiratory flow(PEF),ratio of time to peak(TPTEF/TE),ratio of volume to peak(VPEF/VE)]before and after the treatment,and the incidence of adverse reactions were compared between the two groups.Results:The total effective rate of treatment in the study group was 96.67%(29/30),which was higher than 73.33%(22/30)in the control group,and the difference was statistically significant(P<0.05).The remission time of clinical symptoms such as shortness of breath,nasal obstruction,cough,pulmonary rales and the hospitalization time in the study group were shorter than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the levels of CRP and IL-6 in the two groups were lower than those before the treatment,those in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the PaCO_(2) levels of the two groups were lower than those before the treatment,and that in the study group was lower than that in the control group;the PaO_(2) levels of the two groups were higher than those before the treatment,and that in the study group was higher than that in the control group;and the differences were statistically significant(P<0.05).After the treatment,the levels of VT,TPTEF/TE and VPEF/VE in the two groups were higher than those before the treatment,and those in the study group were higher than those in the control group;the levels of RR and PEF in the two groups were lower than those before the treatment,and those in the study group were lower than those in the control group;and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Terbutaline combined with Budesonide in the treatment of neonatal pneumonia can improve the total effective rate of treatment,shorten the remission time of clinical symptoms and the hospitalization time,reduce the levels of inflammatory factors,and improve the levels of arterial blood gas analysis indexes and lung function indexes.Moreover,it is superior to single Budesonide treatment.